Clinical trials: Pulmonary Hypertension
Pulmonary Hypertension
Latin American Pulmonary Hypertension Registry
The RELAHP registry is a Latin-American multinational, multicenter, prospective observational registry-type cohort study, which pretends to identify clinical characteristics, clinical course, management and outcome of all forms…
- Trial name
- RELAHP (NCT02570737)
- Where
- 8 sites in Argentina, Brazil and 6 more
- Volunteers
- 500 people
- Sponsor
- Asociacion Latinoamericana de Torax
Idiopathic Pulmonary Fibrosis, Pulmonary Hypertension
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a…
- Trial name
- NCT00703339
- Testing
- Treprostinil sodium for inhalation
- Where
- 6 sites in United States
- Volunteers
- 1 people
- Sponsor
- Lung Biotechnology PBC
Pulmonary Arterial Hypertension
Local Open-Label Access Study For Patients Who Completed A1481244 Study In Brazil
The purpose of this study is to provide sildenafil therapy to patients who completed the A1481244 study for the treatment of PAH, and reside in Brazilian States where Revatio™ is not supplied by Health Secretary, and are judged…
- Trial name
- NCT00866983
- Testing
- sildenafil (Revatio) 20 mg TID
- Where
- 2 sites in Brazil
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pulmonary Arterial Hypertension
Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension
This is an open-label, nonrandomized extension to study AC-066A301. The study will assess safety and tolerability of ACT-385781A while providing a means for continuing treatment after ending participation in study AC-066A301.
- Trial name
- Epitome2ext (NCT01470144)
- Testing
- Epoprostenol
- Volunteers
- 41 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension
The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=)…
- Trial name
- NCT03492177
- Testing
- selexipag (Uptravi)
- Where
- 34 sites in United States, Belarus and 14 more
- Volunteers
- 63 people
- Sponsor
- Actelion
Pulmonary Hypertension
Measurements and Characterization of Doppler Signals From the Right Chest in Pediatric and Adult Patients
Recently it has been shown that clear reproducible Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package parametric Doppler, TPD…
- Trial name
- NCT01913457
- Testing
- Ultrasound Doppler
- Where
- 2 sites in United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Echosense Ltd.
Pulmonary Fibrosis, Pulmonary Hypertension
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure.
- Trial name
- NCT00109681
- Testing
- Iloprost Inhalation Solution (Ventavis)
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
This study enrolls patients with pulmonary arterial hypertension (PAH) treated with inhaled treprostinil. During the study, the treatment with inhaled treprostinil will be tapered off and simultaneously replaced with an oral…
- Trial name
- TRANSIT-1 (NCT02471183)
- Testing
- Selexipag
- Where
- 15 sites in United States
- Volunteers
- 34 people
- Sponsor
- Actelion
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
This Phase 2 study (EPIMODE) will evaluate the efficacy and safety of CS1 compared with placebo when added to standard-of-care therapy in participants with pulmonary arterial hypertension.
- Trial name
- EPIMODE (NCT07761572)
- Testing
- CS1
- Volunteers
- 126 people
- Sponsor
- Cereno Scientific AB
Systemic Sclerosis, Pulmonary Arterial Hypertension
Early, Simple and Reliable Detection of Pulmonary Arterial Hypertension (PAH) in Systemic Sclerosis (SSc)
A two-stage prospective observational cohort study in scleroderma patients to evaluate screening tests and the incidence of pulmonary arterial hypertension and pulmonary hypertension
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Trial name
- DETECT (NCT00706082)
- Where
- 83 sites in United States, Austria and 18 more
- Volunteers
- 490 people
- Sponsor
- Actelion
Interstitial Lung Disease, Pulmonary Hypertension
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
- Trial name
- PHINDER (NCT05776225)
- Testing
- Right heart catheterization (RHC)
- Where
- 42 sites in United States
- Volunteers
- 314 people
- Sponsor
- United Therapeutics
Systemic Sclerosis, Pulmonary Hypertension
Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc)
Doppler signals can be recorded from the lung parenchyma by means of a pulsed Doppler ultrasound system incorporating a special signal processing package; i.e.
- Trial name
- NCT02246348
- Testing
- Doppler ultrasound
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- Echosense Ltd.
Pulmonary Hypertension Due to Lung Disease (Disorder)
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3).
- Trial name
- Re-Spire (NCT07285655)
- Testing
- L606
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 344 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmonary Arterial Hypertension
FUTURE 3 Study Extension
The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension…
- Trial name
- FUTURE 3 Ext (NCT01338415)
- Testing
- Bosentan
- Where
- 36 sites in United States, Australia and 16 more
- Volunteers
- 58 people
- Sponsor
- Actelion
Pulmonary Hypertension
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
This study is an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who are currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or…
- Trial name
- FREEDOM-C2 (NCT00887978)
- Testing
- UT-15C SR
- Where
- 62 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- United Therapeutics
Primary Hypertension
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
The purpose of this study is to demonstrate the safety and efficacy of inhaled Iloprost (Ventavis®) among adult Chinese patients with primary pulmonary hypertension, which is in compliance with Chinese SFDA regulation.
- Trial name
- NCT00882947
- Testing
- Ventavis (Iloprost, BAYQ6256)
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Bayer
Pulmonary Arterial Hypertension
A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension
The purpose of this study is to evaluate the effect of macitentan on hemodynamic measures at Week 24 in pediatric populations.
- Trial name
- NCT05167825
- Testing
- Macitentan
- Where
- 11 sites in Japan
- Volunteers
- 7 people
- Sponsor
- Janssen Pharmaceutical K.K.
Scleroderma, Diffuse, Scleroderma, Systemic
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
The purpose of this phase 2 multicenter, randomized, double-blind, placebo-controlled, study is to assess the safety and efficacy of ifetroban in patients with diffuse cutaneous systemic SSc (dcSSc) or SSc-associated pulmonary…
- Conditions
- Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited, Sclerosis, Progressive Systemic
- Trial name
- NCT02682511
- Testing
- Oral Ifetroban
- Where
- 13 sites in United States, India
- Volunteers
- 34 people
- Sponsor
- Cumberland Pharmaceuticals
Pulmonary Arterial Hypertension
Effects of Oral Sildenafil on Mortality in Adults With PAH
This is a blinded study in adult patients with PAH evaluating the relative effects of sildenafil on mortality when administered at the three doses (80 mg, 20 mg or 5 mg, all three times per day [TID]).
- Trial name
- AFFILIATE (NCT02060487)
- Testing
- sildenafil citrate
- Where
- 82 sites in United States, Australia and 21 more
- Volunteers
- 385 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.